^
    4ms
    FL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination. (PubMed, J Exp Clin Cancer Res)
    Together, these results indicate that FL496 is a promising anti-MPM small molecule, and its high anti-MPM potential is worthy of being further explored as a monotherapeutic agent to treat MPM patients in clinical trials.
    Journal • PARP Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • DDX5 (DEAD-Box Helicase 5) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    cisplatin • pemetrexed • FL118 • FL-496
    over4years
    Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. (PubMed, J Exp Clin Cancer Res)
    We then present our data to show the anticancer drug FL118 modulation of these protein targets and RCC cell/tumor growth. Finally, we include additional data to show a promising FL118 analogue (FL496) for treating the specialized type 2 papillary RCC.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • MCL1 (Myeloid cell leukemia 1) • MDM2 (E3 ubiquitin protein ligase) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • MDM4 (The mouse double minute 4) • BIRC5 (Baculoviral IAP repeat containing 5) • EPAS1 (Endothelial PAS domain protein 1) • XIAP (X-Linked Inhibitor Of Apoptosis) • ERCC6 (Excision repair cross-complementation group 6)
    |
    KRAS mutation
    |
    FL118 • FL-496